Singapore, April 1 -- South Korea-based Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and therapeutics, has announced a collaboration with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to explore innovative applications of AI in cancer research.

This collaboration aims to advance research into the tumour microenvironment and immune phenotyping, analysing NCI data to uncover insights that could drive personalised cancer care.

Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyse whole-slide images obtained from NCI's clini...